We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $1.94B
1-Year Est. Return 374.45%
This Fund
S&P 500
This Quarter Est. Return
+35.04%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$1.94B
AUM Growth
+$181M
Cap. Flow
-$1.32M
Cap. Flow %
-0.07%
Top 10 Hldgs %
41.59%
Holding
123
New
29
Increased
30
Reduced
25
Closed
18

Top Buys

Rank Stock Value
1
ROIV icon
Roivant Sciences
ROIV
+$28.3M
2
ANAB icon
AnaptysBio
ANAB
+$26.6M
3
CNTA
Centessa Pharmaceuticals
CNTA
+$20.4M
4
XENE icon
Xenon Pharmaceuticals
XENE
+$19.6M
5
ERAS icon
Erasca
ERAS
+$17.1M

Top Sells

Rank Stock Value
1
VTYX
Ventyx Biosciences
VTYX
+$58.6M
2
WVE icon
Wave Life Sciences
WVE
+$16.9M
3
CGEM icon
Cullinan Oncology
CGEM
+$14.8M
4
ACLX
Arcellx
ACLX
+$14.2M
5
BBIO icon
BridgeBio Pharma
BBIO
+$12.3M

Sector Composition

Rank Sector Weight
1 Healthcare 85.51%
2 Financials 0.66%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CGON icon
76
CALL
CG Oncology
CGON
$6.34B
$4.06M 0.21%
+60,000
New +$3.4M
AVBP icon
77
ArriVent BioPharma
AVBP
$1.55B
$4.04M 0.21%
175,000
+25,000
+17% +$565K
RLAY icon
78
Relay Therapeutics
RLAY
$4.34B
$3.98M 0.21%
+400,000
New +$3.58M
PRQR icon
79
ProQR Therapeutics
PRQR
$240M
$3.98M 0.21%
2,454,278
– –
VRCA icon
80
Verrica Pharmaceuticals
VRCA
$96M
$3.74M 0.19%
707,338
– –
CELC icon
81
CALL
Celcuity
CELC
$4.31B
$3.42M 0.18%
+30,000
New +$3.27M
DTIL icon
82
Precision BioSciences
DTIL
$203M
$3.29M 0.17%
+597,946
New +$2.76M
KPTI icon
83
Karyopharm Therapeutics
KPTI
$216M
$2.79M 0.14%
500,000
-389,575
-44% -$2.97M
SLGL icon
84
Sol-Gel Technologies
SLGL
$272M
$2.77M 0.14%
+35,000
New +$2.53M
CRNX icon
85
Crinetics Pharmaceuticals
CRNX
$8.88B
$2.72M 0.14%
75,000
– –
OACCU
86
Oaktree Acquisition Corp III Life Sciences Unit
OACCU
$2.66M 0.14%
250,000
– –
NXTC icon
87
NextCure
NXTC
$24.4M
$2.58M 0.13%
241,826
-5,468
-2% -$66.8K
IMVT icon
88
Immunovant
IMVT
$8.27B
$2.48M 0.13%
100,000
-100,000
-50% -$2.59M
EQ icon
89
Equillium
EQ
$164M
$2.45M 0.13%
+1,226,310
New +$2.02M
SABS icon
90
SAB Biotherapeutics
SABS
$271M
$2.2M 0.11%
+575,000
New +$2.29M
CORT icon
91
Corcept Therapeutics
CORT
$9.72B
$2.02M 0.1%
+50,000
New +$1.87M
OBIO icon
92
Orchestra BioMed
OBIO
$220M
$1.71M 0.09%
402,550
-170,254
-30% -$725K
KZR
93
DELISTED
Kezar Life Sciences
KZR
$1.7M 0.09%
229,076
– –
MGNX icon
94
MacroGenics
MGNX
$285M
$1.45M 0.07%
500,000
+15,692
+3% +$33.5K
ANL
95
Adlai Nortye
ANL
$743M
$1.14M 0.06%
+164,748
New +$1.1M
ALEC icon
96
Alector
ALEC
$167M
$1.07M 0.06%
+500,000
New +$1M
OKUR
97
OnKure Therapeutics
OKUR
$170M
$998K 0.05%
+240,963
New +$744K
LENZ
98
LENZ Therapeutics
LENZ
$162M
$915K 0.05%
+100,000
New +$1.4M
XFOR icon
99
X4 Pharmaceuticals
XFOR
$360M
$599K 0.03%
145,000
– –
QTTB icon
100
Q32 Bio
QTTB
$255M
$178K 0.01%
27,777
– –
1 2 3
4
5

Similar funds

FM
Foster & Motley Cincinnati, Ohio $1.94B AUM 21.65% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $1.94B AUM 20.3% 1-Year Est. Return
HCL
Heard Capital LLC Chicago, Illinois $1.93B AUM 21.66% 1-Year Est. Return
OCM
Osterweis Capital Management San Francisco, California $1.94B AUM 20.77% 1-Year Est. Return
MWA
Midland Wealth Advisors Effingham, Illinois $1.94B AUM 14.31% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $1.93B AUM 18.43% 1-Year Est. Return
NFG
Nations Financial Group Cedar Rapids, Iowa $1.94B AUM 25.76% 1-Year Est. Return
HC
Hamilton Capital Columbus, Ohio $1.93B AUM

Affinity Asset Advisors's Q1 2026 Portfolio in Review

As of Q1 2026, Affinity Asset Advisors held 123 positions worth $1.94B, up 10% from $1.76B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Affinity Asset Advisors's Q1 2026 filing shows 29 new, 30 increased, 25 reduced and 18 closed positions. Its largest new stake was Enliven Therapeutics: 586,904 shares worth $23M. The largest sale was Ventyx Biosciences, an estimated $58.6M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 77% a quarter earlier, followed by Financials.

  • Affinity Asset Advisors's largest Q1 2026 buy was Enliven Therapeutics: 586,904 shares worth $23M.
  • Affinity Asset Advisors added most to Roivant Sciences in Q1 2026, an estimated $28.3M increase.
  • Affinity Asset Advisors's biggest Q1 2026 reduction was Wave Life Sciences, cutting an estimated $16.9M.
  • Affinity Asset Advisors fully exited Ventyx Biosciences in Q1 2026, selling an estimated $58.6M.
  • Affinity Asset Advisors's ten largest holdings make up 42% of its $1.94B portfolio in Q1 2026.
  • Affinity Asset Advisors opened 29 new positions and closed 18 in Q1 2026.
  • Affinity Asset Advisors's portfolio value rose 10% quarter-over-quarter to $1.94B.

Based on Affinity Asset Advisors's 13F filing for Q1 2026, filed 14 May 2026.